Last reviewed · How we verify
Ibandronate
At a glance
| Generic name | Ibandronate |
|---|---|
| Also known as | Boniva, Bonviva/Boniva, Bonviva, Bondronat, BONIVA® |
| Sponsor | University of California, San Francisco |
| Target | Geranylgeranyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase |
| Modality | Small molecule |
| Therapeutic area | Bone |
| Phase | FDA-approved |
Approved indications
- Hypercalcemia
- Postmenopausal osteoporosis
Common side effects
- Back pain
- Arthralgia
- Dyspepsia
- Diarrhea
- Abdominal pain
- Myalgia
- Headache
- Pain in extremity
Serious adverse events
- Serious adverse reactions (overall incidence)
- Iritis
- Scleritis
- Ocular inflammation
Key clinical trials
- The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation (PHASE4)
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases (PHASE2)
- Denosumab Safety Assessment in Multiple Observational Databases
- Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate (PHASE2)
- Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America
- Efficacy and Safety of Oral Ibandronate in Patients of Liver Cirrhosis With Hepatic Osteodystrophy. (NA)
- Post-fracture Medication and Mortality
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |